Cotinga’s second clinical candidate, COTI-219, is an oral small molecule inhibitor of mutant KRAS protein. KRAS gene mutations occur in up to 30% of all cancers, particularly lung, colorectal, pancreatic and thyroid. COTI‐219 works by blocking KRAS ‐ thereby inhibiting the downstream cell growth and proliferation signaling cascade. In validated cell culture and in vivo preclinical rodent models of colorectal and lung cancers, COTI‐219 as a single agent resulted in significant tumor growth inhibition. Additionally, in a lung cancer rodent model, COTI‐219 performed significantly better in reducing tumor volume compared to several approved standard‐of‐care lung cancer therapies. COTI-219 is undergoing testing in support of an investigational new drug filing in 2018.